SOURCE: Elsevier Business Intelligence

September 18, 2013 14:50 ET

The Major Global Expansion of Rx-to-OTC Switch by 2016

Over $18 Billion in Prescription Drug Sales Could Gain Over-the-Counter Status Soon; Traditional Prescription Drug Lifecycle Management Strategies Altered & Consumer Purchase Opportunities to Be Greatly Expanded; Unique Report Distribution Partnership Between Elsevier Business Intelligence and Francesco International

BEDMINSTER, NJ--(Marketwired - Sep 18, 2013) - Elsevier Business Intelligence, publisher of "The Tan Sheet" and "The Pink Sheet," announced collaboration with Francesco International to distribute a new report: "The Major Global Expansion of Rx-to-OTC Switch by 2016."

"Rx-to-OTC switch is changing dramatically" according to Steven Francesco, CEO of consultancy, Francesco International. The report covers the emergence of new technology, combined with new legislative action and a more proactive regulatory environment. By 2016 "switch" has the potential to have a multi-billion dollar impact on global healthcare outcomes and costs, especially in the cardiovascular, respiratory and central nervous system areas. Switching the $4 billion Lipitor is just one example. Understanding and managing these new business drivers is key.

This report focuses on providing serious strategic and operational guidance to:

  • Companies interested in understanding the importance and potential of business opportunities of these technologically Enhanced OTC (OTC-E™) Drugs.
  • Companies who will experience the impact by a competitor of achieving an Enhanced OTC (OTC-E™) Drugs Rx-to-OTC switch and lowering their sales.

To view the table of contents please visit: Rx-to-OTC Switch Forecast and Guide.

Mr. Francesco states that "We are delighted to partner for the first time with global publisher Elsevier on this important subject. The world of Rx-to-OTC switch will become significantly more active as many new and diverse technology tools will enhance the safe use of numerous prescription drugs in an OTC setting. Moreover, the new openness of the regulators to this new set of healthcare opportunities that will drive down costs should be on the radar screens of all those active in our evolving healthcare industry. The potential financial impact on the US prescription business alone could be in excess of $18 billion in sales by 2016."

"At Elsevier Business Intelligence, we are committed to delivering world-class business intelligence on regulatory, business and reimbursement issues that are vital to the healthcare industry," said Deanna Flanick, Vice President, Sales & Marketing, Elsevier Business Intelligence. "Our strategic distribution agreement with Francesco International is a great step in providing top class Rx-to-OTC switch guidance to CEOs, Business Development Leaders, Rx & OTC teams worldwide."

Purchase your copy of "The Major Global Expansion of Rx-to-OTC Switch by 2016."

Francesco International (www.franint.com) has been involved in lifecycle management and especially Rx-to-OTC switch for 19 years. Francesco International published the newsletter, SWITCH, for 9 years as well as SWITCH Market Impact and Dual Status studies. Francesco International is also known for its "Max the Molecule" software that combines qualitative and quantitative factors which ultimately generates customized financially sensitive scenarios that maximize late stage product lifecycle strategies.

About Elsevier Business Intelligence
Elsevier Business Intelligence (EBI), an Elsevier company built on the heritage of F-D-C Reports, Windhover Information and Medtech Insight, is a global information supplier providing business intelligence on regulatory, business and reimbursement issues that are vital to the healthcare industry. Through a range of products including publications, conferences, databases and reports, EBI places biopharma and medical device professionals, and those who focus on these industries, at the forefront of knowledge, by providing the perfect combination of news and information together with penetrating insight and analysis. EBI (www.elsevierbi.com) has offices in the U.S. in Bedminster, N.J.; Norwalk, Conn.; Rockville, Md.; and Irvine, Calif.

Contact Information

  • Media contact:
    Mike Fergus
    Elsevier Business Intelligence
    +1 908 748 1185
    Email Contact

    Steven Francesco
    CEO
    Francesco International
    +1 973 985 0589 (c)
    Email Contact